Rotshild Victoria, Hirsh Raccah Bruria, Gazawe Muna, Matok Ilan
Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112002, Israel.
The Department of Pharmacy, Clalit Health Services, Jerusalem District, Jerusalem 9112002, Israel.
Cancers (Basel). 2022 May 9;14(9):2344. doi: 10.3390/cancers14092344.
We investigated whether long-term exposure to calcium channel blockers (CCBs) is associated with an increased risk of breast cancer (BCa). We designed a nested case-control study based on data from the Clalit electronic database, the largest Israeli Health Services organization. All newly diagnosed breast cancer (BCa) cases were selected from a cohort of patients with hypertension. Ten controls were matched for each BCa case. The odds ratios (ORs) of BCa among CCBs users were calculated using multivariate conditional logistic regression analyses. A total of 4875 patients with newly diagnosed BCa were identified from the cohort with a median follow-up of 5.15 years. The exposure to CCBs was not associated with an increased risk of BCa (OR = 0.98; 95% CI, 0.92-1.04). Additionally, there was no association between long-term exposure to CCBs (above eight years) and increased BCa risk (OR = 0.91; 95% CI, 0.67-1.21). Higher cumulative doses of CCBs were not associated with an elevated risk of BCa (OR = 0.997; 95% CI, 0.962-1.034, calculated per 1000 DDD). Based on this large population-based study, long-term exposure to CCBs was not associated with an increased risk of BCa. Considering that CCBs are widely used medications, our results provide important safety information on a population level, especially for patients with an increased risk of BCa.
我们研究了长期暴露于钙通道阻滞剂（CCB）是否与乳腺癌（BCa）风险增加相关。我们基于以色列最大的医疗服务机构克拉利特电子数据库中的数据设计了一项巢式病例对照研究。所有新诊断的乳腺癌（BCa）病例均选自高血压患者队列。为每例BCa病例匹配10名对照。使用多变量条件逻辑回归分析计算CCB使用者中BCa的比值比（OR）。从该队列中确定了4875例新诊断的BCa患者，中位随访时间为5.15年。暴露于CCB与BCa风险增加无关（OR = 0.98；95% CI，0.92 - 1.04）。此外，长期暴露于CCB（超过8年）与BCa风险增加之间也没有关联（OR = 0.91；95% CI，0.67 - 1.21）。CCB的累积剂量较高与BCa风险升高无关（OR = 0.997；95% CI，0.962 - 1.034，每1000 DDD计算）。基于这项大型的基于人群的研究，长期暴露于CCB与BCa风险增加无关。鉴于CCB是广泛使用的药物，我们的结果在人群层面提供了重要的安全信息，特别是对于BCa风险增加的患者。
